Nymox Pharmaceutical(NYMXF)
$0.020.00 (0.00%)
NYMXF
Nymox Pharmaceutical financials statements
$0.02
At close:0.00 (0.00%)
Want to see NYMXF full AI Analyst Report?
Nymox Pharmaceutical (NYMXF) Ratios
145 Followers
Nymox Pharmaceutical Ratios
NYMXF's free cash flow for Q4 2024 was $-717.00K. For the 2024 fiscal year, NYMXF's free cash flow was increased by $0.00 and operating cash flow was $-717.00K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Mar 23 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.06 | 0.09 | 0.16 | 0.69 | 0.58 |
| Quick Ratio | 0.06 | 0.09 | 0.16 | 0.69 | 0.56 |
| Cash Ratio | 0.00 | 0.01 | 0.02 | 0.67 | 0.46 |
| Solvency Ratio | -0.42 | -0.60 | -2.32 | -3.12 | -6.43 |
| Operating Cash Flow Ratio | -0.18 | -0.35 | -1.07 | -2.47 | -5.50 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -5.41 | 0.00 | 0.00 |
| Net Current Asset Value | $ -9.31M | $ -6.78M | $ -3.17M | $ -650.00K | $ -912.00K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 1.20 | 0.11 | 0.19 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | -0.24 | -0.36 | 4.71 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | -0.31 | -0.56 | 0.82 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.06 | -0.10 | -0.20 | -3.37 | 24.48 |
| Debt Service Coverage Ratio | -6.07 | -18.87 | -10.82 | -151.65 | -320.31 |
| Interest Coverage Ratio | -6.26 | -18.95 | -136.89 | -154.70 | -320.62 |
| Debt to Market Cap | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.01 | 0.00 | 0.01 | 0.00 | 0.01 |
| Net Debt to EBITDA | 0.00 | 0.02 | -0.08 | 0.19 | 0.04 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 116.26% | 104.88% | 105.92% | 98.86% | 100.26% |
| Return on Assets (ROA) | -742.19% | -686.85% | -1410.53% | -404.68% | -616.98% |
| Return on Equity (ROE) | 45.94% | 66.30% | 278.73% | 1364.32% | -15104.82% |
| Return on Capital Employed (ROCE) | 39.52% | 63.22% | 263.16% | 1380.08% | -5082.93% |
| Return on Invested Capital (ROIC) | 39.52% | 63.22% | 344.61% | 2152.75% | -2637.97% |
| Return on Tangible Assets | -742.19% | -686.85% | -1410.53% | -404.68% | -616.98% |
| Earnings Yield | -110.73% | -47.96% | -19.23% | -22.99% | -11.76% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.35 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1489930.00 | -1501975.00 | -100308.64 | -51617.08 | -37686.28 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 1034.14 |
| Days of Payables Outstanding | 1489930.00 | 1501975.00 | 100308.64 | 51617.08 | 38720.42 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 1034.14 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.02 | -0.03 | -0.04 | -0.06 | -0.12 |
| Free Cash Flow Per Share | -0.02 | -0.03 | -0.04 | -0.06 | -0.12 |
| Dividend Paid and CapEx Coverage Ratio | -1806.00 | 0.00 | -1352.33 | 0.00 | -1636.67 |
| Capital Expenditure Coverage Ratio | -1806.00 | 0.00 | -1352.33 | 0.00 | -1636.67 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | -5.41 | -30.09 | -25.12 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -46.80% | -27.77% | -8.83% | -18.20% | -9.22% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.90 | -2.08 | -5.20 | -4.35 | -8.50 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -0.41 | -1.38 | -14.49 | -59.34 | 1283.97 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.14 | -3.60 | -11.33 | -5.50 | -10.85 |
| Price-to-Operating Cash Flow Ratio | -2.14 | -3.60 | -11.33 | -5.50 | -10.85 |
| Price-to-Earnings Growth (PEG) Ratio | 0.12 | 0.04 | -0.17 | 0.09 | 1.36 |
| Enterprise Value Multiple | -1.08 | -2.18 | -5.32 | -4.20 | -8.50 |
| Enterprise Value | 3.85M | 9.29M | 46.66M | 27.37M | 106.13M |
| EV to EBITDA | -1.08 | -2.18 | -5.32 | -4.20 | -8.50 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -2.13 | -3.57 | -11.49 | -5.26 | -10.80 |
| EV to Operating Cash Flow | -2.13 | -3.57 | -11.50 | -5.26 | -10.81 |
| Tangible Book Value Per Share | -0.10 | -0.07 | -0.03 | -0.01 | 0.00 |
| Shareholders’ Equity Per Share | -0.10 | -0.07 | -0.03 | -0.01 | 0.00 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.04 | -0.05 | -0.10 | -0.07 | -0.15 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.16 | 1.05 | 1.01 | 1.01 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.42 | 0.58 | 0.46 | 0.79 | 0.78 |
Currency in USD
